Total Funding
52
52
Total FundingVenture - Series Unknown raised
Growth Score 52 in past quarter
-3 pts
Heat Score 52 in past quarter
-8 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
78091
Orbus Therapeutics is dedicated to developing products that treat rare diseases.
- Jason Levin: Chief Operating Officer, Co-Founder, Board memberPast Role: Sorbent Therapeutics, Chief Business Officer
- Bob Myers: Founder, President, and Chief Executive Officer
About the Company
They at Orbus are committed to bringing innovative products to the extremely underserved patients affected by rare diseases. They are focused and passionate about bringing a more positive outcome to patients facing life-threatening or significantly life-altering diseases. Currently, Orbus Therapeutics is working to develop and commercialize
eflornithine in North America.
The company was founded in 2012 and is headquartered in Palo Alto, California.